How should disulfiram be used in adult patients with alcohol use disorder, including indications, contraindications, dosing, and monitoring?

Disulfiram Use in Alcohol Use Disorder

Disulfiram is contraindicated in patients with alcoholic liver disease and should be reserved as a second-line treatment option only for highly selected patients without hepatic impairment who have strong motivation for abstinence and reliable supervision. 1, 2

Contraindications and Safety Concerns

Absolute Contraindications

• Patients with alcoholic liver disease (ALD) or hepatic insufficiency should not receive disulfiram, as it is explicitly contraindicated according to multiple major guidelines including the American Association for the Study of Liver Diseases, French Association for the Study of the Liver, and Korean Association for the Study of the Liver 1, 2
• The drug must never be administered until the patient has abstained from alcohol for at least 12 hours 3
• Patients over 50 years of age should never undergo supervised alcohol-drug test reactions 3

Mechanism and Risks

• Disulfiram inhibits aldehyde dehydrogenase (ALDH), causing toxic acetaldehyde accumulation when alcohol is consumed 1, 2
• This produces severe aversive reactions including flushing, dizziness, nausea, vomiting, arrhythmia, dyspnea, headache, tachycardia, and hypotension 1, 2, 3
• Cardiac, hepatic, and neurologic toxicity can occur even within standard dosage ranges (250-500 mg/day) 4

Dosing Regimen

Initial Phase

• Maximum 500 mg daily as a single dose for 1-2 weeks 3
• Usually taken in the morning, though may be taken at bedtime if sedation occurs 3
• Dosage may be adjusted downward to minimize sedative effects 3

Maintenance Phase

• Average maintenance dose is 250 mg daily (range 125-500 mg) 3
• Should not exceed 500 mg daily 3
• Daily, uninterrupted administration must continue until the patient is fully recovered socially and permanent self-control is established 3
• Maintenance therapy may be required for months or even years 3

Patient Selection Criteria

Ideal Candidates (Narrow Selection)

• Older patients with greater social stability 4, 5
• Highly motivated individuals committed to abstinence 4, 5
• Patients with adequate family support and supervision 4, 5
• No medical contraindications (particularly no liver disease) 1, 2, 5
• No psychiatric contraindications 5

Common Pitfall

• Patients may report drinking without symptoms while supposedly taking disulfiram—this indicates non-compliance (disposing of tablets) rather than drug ineffectiveness 3
• Supervised administration (preferably crushed and mixed with liquid) is essential to ensure compliance 3, 6

Efficacy Evidence

Short-term Outcomes

• Supervised disulfiram treatment shows some effect on short-term abstinence (up to 6 months), days until relapse, and reduction in drinking days compared to placebo 4, 6
• Six of eleven randomized controlled trials reported significantly better abstinence rates with disulfiram 6
• Efficacy is primarily limited to compliant patients under supervision 4, 6

Long-term Outcomes

• Disulfiram has no proven effect on long-term outcome of alcoholism 4
• Long-term effect on abstinence has not been adequately evaluated 6
• Only 3 studies of 12 months duration showed significance regarding days until relapse or reduction in drinking days 6

Critical Limitation

• Disulfiram prescribed without accompanying education, counseling, and concomitant alcoholism therapy is not beneficial 4
• When used alone without proper motivation and supportive therapy, it is unlikely to have substantive effect on drinking patterns 3

Preferred Alternatives for Patients with Liver Disease

First-Line Option

• Baclofen is the preferred medication for maintaining alcohol abstinence in patients with liver cirrhosis, as it has demonstrated safety and efficacy in this population 1, 2
• Dosing up to 80 mg/day does not generally require adjustment for liver disease, though more gradual dose increases are recommended in severe hepatic disease 1

Other Options

• Acamprosate has no hepatic metabolism and its use is not changed by presence of liver disease 1
• Naltrexone and nalmefen are also contraindicated in hepatic insufficiency, though the absolute nature of these contraindications lacks solid supporting data 1

Monitoring Requirements

Compliance Monitoring

• Direct observation of tablet ingestion is essential for reliable efficacy assessment 3
• Urinary 5-hydroxytryptophol (5HTOL) to 5-hydroxyindole-3-acetic acid (5HIAA) ratio testing can detect both disulfiram compliance and alcohol relapse 7
• Individual dose-titration using 5HTOL/5HIAA testing may improve therapeutic effectiveness 7

Safety Monitoring

• Continuous clinical supervision required to monitor for efficacy and side effects 4
• Potassium levels should be monitored, particularly in patients on digitalis, as hypokalemia has been reported 3
• Monitor for hepatic, cardiac, and neurologic toxicity 4

Management of Disulfiram-Alcohol Reaction

Severe Reactions

• Institute supportive measures to restore blood pressure and treat shock 3
• Administer oxygen or carbogen (95% oxygen and 5% carbon dioxide) 3
• Give vitamin C intravenously in massive doses (1 g) 3
• Consider ephedrine sulfate and intravenous antihistamines 3
• Monitor potassium levels closely 3

Guideline Recommendations

The 2020 American Association for the Study of Liver Diseases explicitly states that disulfiram is not recommended for use in patients with ALD and is not included in their table of relapse prevention medications 1. A 2020 systematic review and network meta-analysis found limited evidence to support disulfiram's effect on abstinence, noting particular challenges in conducting placebo-controlled trials due to patients easily determining if they are taking the medication 1. Recent 2024 expert opinion reinforces that disulfiram should remain second-line treatment for most patients with AUD, reserved only for highly selected individuals without medical or psychiatric contraindications 5.